Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 10,000 shares of Genomic Health stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $48.89, for a total value of $488,900.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Kimberly J. Popovits also recently made the following trade(s):
Get Genomic Health alerts: On Monday, May 14th, Kimberly J. Popovits sold 10,000 shares of Genomic Health stock. The shares were sold at an average price of $38.09, for a total value of $380,900.00. On Monday, April 16th, Kimberly J. Popovits sold 15,000 shares of Genomic Health stock. The shares were sold at an average price of $33.19, for a total value of $497,850.00.GHDX stock traded up $0.16 during mid-day trading on Monday, hitting $49.75. 265,138 shares of the stock were exchanged, compared to its average volume of 209,295. Genomic Health, Inc. has a 12 month low of $26.54 and a 12 month high of $53.65. The firm has a market cap of $1.75 billion, a P/E ratio of 4,975.00 and a beta of 0.64.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.08. Genomic Health had a positive return on equity of 3.15% and a negative net margin of 1.95%. The firm had revenue of $92.60 million during the quarter, compared to analyst estimates of $88.95 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue was up 12.5% compared to the same quarter last year. equities analysts expect that Genomic Health, Inc. will post 0.47 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the company. ValuEngine raised Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 7th. LADENBURG THALM/SH SH lowered Genomic Health from a “buy” rating to a “neutral” rating and set a $33.00 price target for the company. in a research note on Wednesday, June 13th. Canaccord Genuity lifted their price target on Genomic Health from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, June 4th. BidaskClub raised Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Finally, Zacks Investment Research raised Genomic Health from a “hold” rating to a “strong-buy” rating and set a $42.00 price target for the company in a research note on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. Genomic Health currently has a consensus rating of “Hold” and an average target price of $34.22.
A number of hedge funds have recently modified their holdings of GHDX. Teacher Retirement System of Texas purchased a new position in shares of Genomic Health in the fourth quarter worth about $242,000. Virtu Financial LLC purchased a new position in shares of Genomic Health in the fourth quarter worth about $261,000. Guggenheim Capital LLC purchased a new position in shares of Genomic Health in the first quarter worth about $264,000. MetLife Investment Advisors LLC purchased a new position in shares of Genomic Health in the fourth quarter worth about $301,000. Finally, Legal & General Group Plc increased its holdings in shares of Genomic Health by 67.8% in the first quarter. Legal & General Group Plc now owns 12,300 shares of the medical research company’s stock worth $385,000 after buying an additional 4,968 shares during the period. 89.77% of the stock is owned by hedge funds and other institutional investors.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
No comments:
Post a Comment